Acute worsening of glycemic control in a patient with type 2 diabetes and non-small cell lung cancer after administration of lorlatinib

A case with non-small cell lung cancer exhibited extreme hyperglycemia after lorlatinib treatment, whose adverse effects on hyperglycemia is little known. But, the lorlatinib could be continued by intensifying diabetes treatment, indicating the importance of glucose monitoring during lorlatinib administration, and of adequate intensification of treatment for such hyperglycemia.